EP0819681A3 - N-(4-Aryl-thiazol-2-yl)-sulfonamide und deren Verwendung - Google Patents

N-(4-Aryl-thiazol-2-yl)-sulfonamide und deren Verwendung Download PDF

Info

Publication number
EP0819681A3
EP0819681A3 EP97111745A EP97111745A EP0819681A3 EP 0819681 A3 EP0819681 A3 EP 0819681A3 EP 97111745 A EP97111745 A EP 97111745A EP 97111745 A EP97111745 A EP 97111745A EP 0819681 A3 EP0819681 A3 EP 0819681A3
Authority
EP
European Patent Office
Prior art keywords
nitro
oder
nieder
amino
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97111745A
Other languages
English (en)
French (fr)
Other versions
EP0819681A2 (de
Inventor
Andrea Cesura
Stephan Rover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP0819681A2 publication Critical patent/EP0819681A2/de
Publication of EP0819681A3 publication Critical patent/EP0819681A3/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Sulfonamid-Derivaten der allgemeinen Formel
Figure 80000001
worin
R
nieder-Alkyl, Phenyl, Benzyl, Naphthyl, Pyridyl oder Thienyl, gegebenenfalls einfach oder mehrfach substituiert durch nieder-Alkyl, nieder-Alkoxy, nieder-Alkyl-carbonyl-amino, Halogen, Cycloalkyl, Nitro, Amino, Methylendioxy, Phenoxy oder Benzyloxy, wobei die aromatischen Ringe wiederum durch Nitro, Halogen oder Amino substituiert sein können,
R1-R4
Wasserstoff, Halogen, Hydroxy, nieder-Alkyl, Nitro, Cyano, Amino, nieder-Alkoxy, Benzyloxy, Trifluormethyl oder Phenyl, gegebenenfalls einfach oder mehrfach substituiert durch nieder-Alkyl, Trifluormethyl, Nitro, Amino oder Hydroxy,
und wobei R1 und R2 oder R2 und R3 zusammen einen Benzolring bilden können, der gegebenenfalls substituiert sein kann durch Halogen, Trifluormethyl, Nitro, nieder-Alkyl oder nieder-Alkoxy, bedeuten, sowie von deren pharmazeutisch annehmbare Salze als Kynurenin-3-Hydroxylase Hemmstoffe bei der Bekämpfung oder Verhütung von neurodegenerativen Erkrankungen, neurologischen Erkrankungen als Folge einer Aktivierung des Immunsystems, von psychiatrischen Leiden bzw. zur Herstellung entsprechender Arzneimittel.
EP97111745A 1996-07-19 1997-07-10 N-(4-Aryl-thiazol-2-yl)-sulfonamide und deren Verwendung Ceased EP0819681A3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96111661 1996-07-19
EP96111661 1996-07-19

Publications (2)

Publication Number Publication Date
EP0819681A2 EP0819681A2 (de) 1998-01-21
EP0819681A3 true EP0819681A3 (de) 1998-02-04

Family

ID=8223010

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97111745A Ceased EP0819681A3 (de) 1996-07-19 1997-07-10 N-(4-Aryl-thiazol-2-yl)-sulfonamide und deren Verwendung

Country Status (23)

Country Link
US (2) US5877193A (de)
EP (1) EP0819681A3 (de)
JP (1) JP2991679B2 (de)
KR (1) KR100247672B1 (de)
CN (1) CN1176101A (de)
AU (1) AU725496B2 (de)
BR (1) BR9704023A (de)
CA (1) CA2210613A1 (de)
CO (1) CO4900053A1 (de)
CZ (1) CZ227397A3 (de)
HR (1) HRP970393A2 (de)
HU (1) HUP9701193A3 (de)
IL (1) IL121298A (de)
MA (1) MA24273A1 (de)
MX (1) MX9705385A (de)
NO (1) NO973338L (de)
NZ (1) NZ328331A (de)
PE (1) PE91298A1 (de)
PL (1) PL321203A1 (de)
SG (1) SG91796A1 (de)
TR (1) TR199700653A2 (de)
YU (1) YU30297A (de)
ZA (1) ZA976222B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725138D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Thiophenesulfonamide compounds
GB9725141D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Benzenesulfonamide compounds
US6211185B1 (en) 1999-05-05 2001-04-03 Veterinary Pharmacy Corporation Concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution, and a suspending agent
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
CA2436526C (en) * 2000-12-13 2010-10-19 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
EA200400707A1 (ru) 2001-11-22 2004-10-28 Биовитрум Аб Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
FR2849599B1 (fr) * 2003-01-07 2006-12-29 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
JPWO2005054216A1 (ja) * 2003-12-01 2007-06-28 株式会社リバース・プロテオミクス研究所 新規抗癌剤「スルコキシン」
DK2420494T3 (en) * 2006-08-16 2015-01-12 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase
DK2054397T3 (en) 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
CN101990434B (zh) * 2008-01-15 2013-07-31 西佳技术公司 用于治疗沙粒病毒感染的抗病毒药物
WO2009124086A2 (en) * 2008-04-04 2009-10-08 Siga Technologies, Inc. Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN101602687A (zh) * 2008-06-13 2009-12-16 上海特化医药科技有限公司 6-硝基苯乙酮类化合物、其制备方法及用途
PT2750677T (pt) * 2011-08-30 2017-07-03 Chdi Foundation Inc Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos
CN102633695A (zh) * 2012-04-05 2012-08-15 天津理工大学 一种4-异丙基苯磺酰氯的制备方法和工艺
CN102633687B (zh) * 2012-04-05 2016-06-08 天津瑞岭化工有限公司 一种对位取代烷基苯磺酰氯的制备方法和工艺
CN102627589A (zh) * 2012-04-05 2012-08-08 天津理工大学 一种两步合成制备4-异丙基苯磺酰氯的方法和工艺
CN102633696A (zh) * 2012-04-05 2012-08-15 天津理工大学 一种两步合成制备对位取代烷基苯磺酰氯的方法和工艺
EP3345596B1 (de) * 2012-09-21 2021-01-20 Rhode Island Hospital Beta-hydrolase-hemmer zur behandlung von krebs
AU2017268006B2 (en) 2016-05-20 2021-03-11 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
RU2760303C2 (ru) 2016-12-09 2021-11-23 Ксенон Фармасьютикалз Инк. Соединения бензолсульфонамидов и их использование в качестве терапевтических средств
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
CR20210099A (es) 2018-08-31 2021-06-24 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapèuticos
CN112638898B (zh) 2018-08-31 2024-04-09 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途
CN114516807B (zh) * 2022-02-24 2023-11-17 南京大学 一种含硝基多取代芳香二胺单体及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016650A1 (fr) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016650A1 (fr) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHAABAN, I. ET AL: "Synthesis of 2-(2-substituted aminothiazol-4-yl)hydrochinone and p-benzochinone derivatives as antibacterial agents", SCI. PHARM., vol. 52, no. 1, 1984, pages 51 - 58, XP002048407 *
CHEMICAL ABSTRACTS, vol. 118, no. 13, 1993, Columbus, Ohio, US; abstract no. 125015v, XP002048409 *
CHEMICAL ABSTRACTS, vol. 89, no. 25, 1978, Columbus, Ohio, US; abstract no. 215283t, XP002048410 *
CHEMICAL ABSTRACTS, vol. 97, no. 5, 1982, Columbus, Ohio, US; abstract no. 38873c, XP002048408 *
CHIO., L.C. ET AL: "Identification of a class of sulfonamides highly active against dihydropteroate synthase from Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium", ANTIMICROB. AGENTS CHEMOTHER., vol. 40, no. 3, March 1996 (1996-03-01), pages 727 - 733, XP002048405 *
CHOUDHARI, S.R. ET AL: "Synthesis of 2-aminothiazole derivatives", J. INDIAN. CHEM. SOC., vol. 55, no. 4, 1978, pages 401 - 404 *
EL-SHUKRY GABER: "Research in organic chemistry", J. IRAQI ACAD., vol. 31, no. 4, 1980, pages 93 - 110 *
GAGIU, F. ET AL: "Mitodepressive Substanzen", DIE PHARMAZIE, vol. 27, no. 3, 1972, pages 166, XP002048406 *
GOMMAA, A.M.: "Synthesis of some biologically active substituted thiazole derivatives", IZV. KHIM., vol. 24, no. 3, 1991, pages 448 - 452 *
SHUKRIJ. ET AL: "Neue SUlfathiazole", WISS. Z. UNIV. HALLE, vol. 33, no. 3, 1984, pages 91 - 93, XP002048404 *

Also Published As

Publication number Publication date
EP0819681A2 (de) 1998-01-21
HUP9701193A2 (hu) 1999-02-01
CO4900053A1 (es) 2000-03-27
US5877193A (en) 1999-03-02
JP2991679B2 (ja) 1999-12-20
NO973338D0 (no) 1997-07-18
PE91298A1 (es) 1998-12-31
NZ328331A (en) 1999-05-28
KR100247672B1 (ko) 2000-04-01
MA24273A1 (fr) 1998-04-01
JPH1067761A (ja) 1998-03-10
NO973338L (no) 1998-01-20
CZ227397A3 (cs) 1998-02-18
BR9704023A (pt) 1998-11-17
HU9701193D0 (en) 1997-09-29
SG91796A1 (en) 2002-10-15
TR199700653A2 (xx) 1998-02-21
AU725496B2 (en) 2000-10-12
KR980008228A (ko) 1998-04-30
HUP9701193A3 (en) 2000-08-28
YU30297A (sh) 2000-10-30
IL121298A0 (en) 1998-01-04
US5958910A (en) 1999-09-28
PL321203A1 (en) 1998-02-02
HRP970393A2 (en) 1998-04-30
CN1176101A (zh) 1998-03-18
IL121298A (en) 2001-03-19
AU2875297A (en) 1998-01-29
ZA976222B (en) 1998-01-19
CA2210613A1 (en) 1998-01-19
MX9705385A (es) 1998-04-30

Similar Documents

Publication Publication Date Title
EP0819681A3 (de) N-(4-Aryl-thiazol-2-yl)-sulfonamide und deren Verwendung
ATE258067T1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
ATE13422T1 (de) Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems.
DE69429078T2 (de) Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
SE8601103D0 (sv) Neue, schwefelhaltige 5-substituierte benzimidazol-derivate und verfahren zu ihrer herstellung
BR0111980A (pt) Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda
RU93046497A (ru) Фенильные гетероциклические производные, способ их получения, фармацевтическая композиция и промежуточный продукт
ATE128143T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3 one-derivate und verfahren zu ihrer herstellung.
DE59510042D1 (de) 2,2-dichloralkancarbonsäuren, verfahren zu ihrer herstellung diese enthaltende arzneimittel, und ihre verwendung zur behandlung der insulinresistenz
IT1293807B1 (it) Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
BR9508295A (pt) Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopamina
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
DE60101559T2 (de) Benutzung von comt-inhibitoren als analgetika
PT90269A (pt) Processo para a preparacao de carboxamidas hetero-alifaticas e de composicoes farmaceuticas que as contem
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
ATE15181T1 (de) (z)-1-aryl-2-aminomethyl-cyclopropan-carboxylat , ihre herstellung und ihre verwendung als arzneimittel fuer die behandlung von verschiedenen schmerzen.
DE10150517A1 (de) Verwendung von Phosphodiesterase IV-Inhibitoren
US5728713A (en) Use of quinoline-3-carboxamide compounds
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
ATE359995T1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
KR890000500A (ko) 3,4-디하이드로-2-알킬-3-옥소-N-아릴-2H-[1]벤조티에노-[3,2-e]-1,2- 티아진-4-카복스 아미드-1, 1-디옥사이드
DE69611727D1 (de) Verwendung von phenoxypyridinderivaten zur behandlung der durch stoerungen des dopaminsystems verursachten erkrankungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19980608

17Q First examination report despatched

Effective date: 19980709

AKX Designation fees paid

Free format text: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 277/52 A, 7A 61K 31/426 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20011103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1008217

Country of ref document: HK